- 4 evaluable GNAQ/11 mutation skin melanoma patients enrolled in Stage 1 cohort with a 100% Disease Control Rate (excluding 1 non-evaluable) and 1 confirmed partial response by RECIST 1.1 guidelines
- 15 additional skin melanoma patients harboring GNAQ/11 mutations will be enrolled in Stage 2 of cohort expansion in Phase 2 GNAQ/11 basket arm of the clinical trial
- Dosed first leiomyosarcoma patient in the Phase 2 GNAQ/11 basket arm, expanding the tissue-agnostic approach to additional solid tumors
- IDE196 tablet formulation complete and successfully introduced in ongoing clinical trial, including the IDE196-binimetinib combination arm and the GNAQ/11 basket arm
- 13-week preclinical toxicology studies in 2 species are now complete with receipt of submission-ready audited draft reports
PR Newswire
SOUTH SAN FRANCISCO, Calif., July 16, 2020